Tumor RNA Transfected Dendritic Cell Vaccines
The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.
Biological: Tumor RNA transfected dendritic cells
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Tumor RNA Transfected Dendritic Cell Vaccines|
|Estimated Study Completion Date:||September 2005|
The specific aims are: 1) to evaluate, in a phase I clinical trial, the safety of vaccinating patients with dendritic cells transfected with RNA from autologous cancer cells; 2) to analyze the T cell responses induced by the treatment; and 3) to improve the efficacy of the treatment by developing methods to increase the induction of CD4+T cell responses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00108264
|United States, North Carolina|
|Durham VA Medical Center|
|Durham, North Carolina, United States, 27705|